Risperdal Users Five Times Likelier To Develop Gynecomastia
A newly published study involving thousands of Risperdal patients has linked the drug to the development of gynecomastia, or excessive male breast growth. The publication of the research in the Journal of Child and Adolescent Psychopharmacology comes as the drugs’ manufacturers face hundreds of Risperdal lawsuits over its alleged association with the condition.
According to the August 19th report, the authors of the study looked at data on more than 401,900 boys and men aged 15-to-25 contained in the IMS LifeLink database, and identified a cohort of new gynecomastia cases. For each case, 10 controls were selected and matched to the cases by age, follow-up, and calendar times.
“There were 1556 cases of gynecomastia and 15,560 corresponding controls. Current users of risperidone had approximately four times the risk of developing gynecomastia than non-users (RR=3.91, 95% CI=2.01–7.62),” the study authors wrote. “When the analysis was stratified to children and adolescents (≤18 years of age) taking risperidone, the risk of gynecomastia was five times higher than for non-users (RR=5.44, 95% CI=1.50–19.74).”
Risperdal Gynecomastia Litigation
The findings of the study seem to back the allegations contained in hundreds of product liability lawsuits involving Risperdal and gynecomastia. The majority of these claims are currently pending in a mass tort litigation now underway in Pennsylvania’s Philadelphia Court of Common Pleas. Two such cases have already gone to trial in that litigation, the first of which ended with a $2.5 million verdict in favor of the plaintiff. While a second jury found that Risperdal’s gynecomastia warnings were inadequate, the plaintiff was not awarded any damages because jurors could not conclude that the drug had causes his breast growth.
A third Risperdal gynecomastia case was scheduled for trial in May, but settled out-of-court for an undisclosed amount. More trials will get underway in the Pennsylvania litigation next month.
Bernstein Liebhard LLP is now representing a number of Risperdal gynecomastia plaintiffs. If you are interested in joining this litigation, please call 877-779-1414 to learn more.